Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation

Launched by CHANG GUNG MEMORIAL HOSPITAL · May 30, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how modern radiotherapy techniques can reduce long-term effects on the heart and lungs in patients with lymphoma, particularly those with tumors located in the mediastinum (the area in the chest between the lungs). Researchers aim to monitor the health of these vital organs using tests like echocardiograms (ultrasound of the heart) and lung function tests before, during, and after treatment. The goal is to understand how these newer treatment methods can help patients receive effective care while minimizing potential side effects.

To be eligible for the trial, participants should be over 15 years old and have a confirmed diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma. They should also be planning to receive radiation therapy that targets the mediastinum after completing their chemotherapy. Participants will receive thorough evaluations before starting treatment and will have regular follow-up appointments for up to three years to track their heart and lung health. Overall, this study aims to improve the safety and effectiveness of treatment for lymphoma patients while ensuring their long-term health is carefully monitored.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with an age of more than 15 years old when encountering local radiotherapy
• • Histologically confirmed Hodgkin lymphoma or non-Hodgkin lymphoma
• • A patient with resected thymoma referred for undergoing postoperative adjuvant radiotherapy is also acceptable and might be feasible
• • The intended radiation field should involve the mediastinum region
• • Malignant lymphoma patients who have undergone systemic chemotherapy with appropriate intensity and cycles tailored to the histologic subtype and oncological staging should start receiving RT within one month after restaging oncological surveys are performed before the course of mediastinal RT. Patient who must complete standard chemotherapy appropriate for the histologic subtype and staging of lymphoma and also be able to start radiation therapy within one month after restaging oncological surveys performed after completing chemotherapy
• • Patients should have a fair to good performance status better than Eastern Cooperative Group (ECOG) of 2.
• • Life expectancy of at least 12 months
• Exclusion Criteria:
• • Pregnant or breastfeeding
• • Prior therapeutic radiation therapy delivered to breast, thoracic, or head \& neck
• • Patients who have a serious medical illness